Upload
shawna-houghland
View
226
Download
0
Tags:
Embed Size (px)
Citation preview
Personalized Medicine - Genomics
Maria Judit Molnar
2014
The Personal Genome Project is a long term, large cohort study
Aims to sequence and publicize the complete genomes and medical records of 100,000 volunteers, in order to enable research into personal genomics and personalized medicine.
It was initiated by Harvard University in 2005.
The Personal Genome Project is a long term, large cohort study
Aims to sequence and publicize the complete genomes and medical records of 100,000 volunteers, in order to enable research into personal genomics and personalized medicine.
It was initiated by Harvard University in 2005.
Personal Genome Project
• The individuals agree to make their genome and their health records public.
• „volunteers… willing to share their genome sequence and many types of personal information with the research community and the general public,
• Aim: to understand genetic and environmental contributions to human traits.”
The project publish the • genotype (the full DNA sequence), • phenotype: medical records, various
measurements, MRI images, etc. • all data are within the public domain• made available over the Internet so that
researchers can test various hypotheses about the relationships among genotype, environment and phenotype.
Risks
Dealing with bad news
Genotype and phenotype
Some variants predicting severe effects in the PGP-10
Some variants predicting severe effects in the PGP-10
Participant Variant Putative effect
PGP5 (hu9385BA) PKD1-R4276W Autosomal dominant polycystic kidney disease
PGP6 (hu04FD18) MYL2-A13T Hypertrophic cardiomyopathy
PGP9 (hu034DB1) SCN5A-G615E Long QT syndrome
PGP10 (hu604D39) PKD2-S804N Autosomal dominant polycystic kidney disease
PGP10 (hu604D39) RHO-G51A Autosomal dominant retinitis pigmentosa
PGP CanadaPGP Canada
PGP UKPGP UKPGP HarwardPGP Harward
Risk-Benefit Ratio
The roots
„ It’s far more important to know what person the disease has than what disease the person has.”
Hippocrates (BC. 400)
The paradigm of the classic treatments
SymptomDiagnosis TreatmentDosage
Non specificNon selectivUniformized
Phenotype
Trial and error
Does not evaluate the different therapeutic response - the blockbuster concept
The medicine in the XX. century
• „One fits to all”
• The target is the disease
• Evidence based medicine– statistical approach using the rule of large numbers,
resulting in statistically meaningful conclusions
Paracelsus
(1493-1541)
“The dose makes the poison.”
But differently for genetically different individuals
The revolution of the molecular biology:
Right DiseaseRight DiseaseRight PatientRight Patient
Right DrugRight DrugRight TimeRight Time
Ineffective therapies – waste money
Hypertension Drugs 10-30%
ACE Inhibitors $390 million – $1.2 billion
Heart Failure Drugs 15-25%
Beta Blockers $345 million – $575 million
Anti Depressants 20-50%
SSRIs $2.3 billion – $5.8 billion
Cholesterol Drugs 30-70%
Statins $3.8 billion – $8.8 billion
Asthma Drugs 40-70%
Beta-2-agonists $560 million – $1.0 billion
The results in 2013
• The most drugs are not or partially effective in the 60% of the treated patients
• Side effects are responsible for– 100,000 death– 2 million hospitalisations– 100 billion USD cost for healthcare in USA– 50%- of the cases is related genetics
Personalized Medicine: The Answer?
Definition
The use of information and data from a patient’s genotype andphenotype (level of gene expression and/or clinicalinformation) to:
– stratify disease
– select a medication
– provide a therapy
– initiate a preventative measure that is particularly suited to that patient at the time of administration
Personalized Medicine is an emerging practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease
Focus on the clinical needs!
“Bench to Bedside” “Bedside to Bench to Bedside”
However genomic determinate the potential biological and physiological reactions of the individual, we can not miss the analysis of the environmental effects.
The bigest weakness of the clinic nowadays is the lack of the exact diagnosis and the inapropriate determination of the stadium of the disease.
The classical therapy:Uniformisation
Observation Treatment Uncertain respond
Observation Testing (Biomarker) Treatment Predictedrespond
Targeted therapy:Differenciate, diagnostics and drug co-development
Independently from the heterogeneity of the population try to get in large cohorts positiv results/risk ratio with the treatment (clinical utility)
Targeted therapies help by identificatioon of the patients with the best respond and less side effects
Biomarkers are such diagnostic tools, wich may predict the therapeutic respond to a certain drug
Healthcare pressure:Risk / benefit ratio
Economical pressure:Cost / benefit ratio
New Technologies:Expanding possibilities
Needs of highly differentiated healthcare, which effects the health of the person and society
Only the really innovative medicine is justifiedInnovative ~ Personalized, Differentiated
The key drivers of the paradigm change in the healthcare - 2013
The Power of Information - Moore’s law
Computer processing power is doubling every 18 monthsAmount of data is doubling every 18 months
Power of technology
Technological improvement
• Genomic revolution of the end of the 20.th century– Completing the Human Genom Project (2000)
• „Only” 25 thousand genes – vs 100 thousand– Computed genotyping, DNA microarray– „$1000 Genom”
• „Nobody expected”:– 25thousand genes – 9 million SNP– The function of 30% of the genes is uncleared– The role of deletions, duplications, CNVs– Microsatellite polymorphisms– Epigenetic
Forrás: Jose de Leon, Pharm Res 59 (2009) 81-89 alapján
PM impacts diagnostic categories
A new era in genomics medicine?
• Human genome project
• Direct-to-consumer genomics
• Intellectual property disputes– Catalona– Myriad Genetics– Henrietta Lacks
• Personal Genome Project
Drug discovery paradigm shift: a problem or an opportunity?
• Ever increasing demand for safer medicine• Stark realization that drug discovery is expensive and slow
– shrinking budgets, consolidation, outsourcing• Current drug inventory is large, diverse and possibly has a
lot more to offer than was initially thought• Increasing availability of genomic data and tools to
use/understand it
Genomic data in the patient care
Monogenic vs Complex Disorders
Monogenic Disorders: Success story
Complex disorders: limited success rate
Age related macula degeneration
Apolipoprotein E Genotype and Alzheimer Disease
• Metaanalysis of 40 study• 5.930 patient and 8.607 control
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline and Alzheimer Disease
Thorlakur Jonsson et al.
Nature 2012; 488, 96–99 (02 August 2012) doi:10.1038/nature11283
A coding mutation (A673T) in the APP gene protects against Alzheimer’s disease
This substitution results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro.
The change of disease concept
Traditional: reductionist, one single factor
Causal factor Disease
Basic risk
Environmental factors
Preclinicalprogression
Disease onset
Diseaseprogression
Irreversiblechanges
New conception: multifactorial
Egészségre Egészségre gyakoroltgyakorolt
hatáshatásSNPSNP combinations combinations
Other SNPsEnvironment
Köztesfenotípus
Effect on the Effect on the healthhealthIntermedier
phenotype
Complex, polygenic, multifactorial disease
Egészségre Egészségre gyakoroltgyakorolt
hatáshatásMutMutationation
Other SNPsEnvironment
intermediateintermediatephenotypephenotype
Effect on the Effect on the healthhealth
Intermedierphenotype
Monogenic disease
New Disease Concept
The old paradigm: Treatment of the disease
0
10
20
30
40
50
60
1. n.év 2. n.év
Diagnosis
Select drug
Switch drug
Switch drug again
Time
Reactive medical care
Dis
ease
sev
erity
To effective health management
0
5
10
15
20
25
30
35
1. n.év 2. n.év
ScreeningPredisposition
Diagnosis/Prognosis
Right Drug
Time
Efficient medical care
Dis
ease
sev
erity
Monitoring
Social expectations
• Cheaper, more effective drug development
Forrás: Business Insights: Expanding Applications of Personalized Medicine, 2009
Social expectations
United StatesDepartmentof Genetic Identity
Louis Cipher12230 Pacific Ave.Los Angeles, CA 90024
HolographicSequence Data
ISSUE DATE0 2 - 0 5 -2 0 0 1
IDENTIFICATION NUMBERJ Q-85 3-64 3-8 49 3-23 07
This card required for allmedical services: tamperingvoids National Health Coverage
Scruples
• Healthpolitical questions• Regulatory issues• Financing aspects• Insurance consequence
– USA: Genetic Information Nondiscrimination Act (2008)
• Ethical questions– How to sell the test laymens?
FDA prohibited to sell the testFDA prohibited to sell the test
What will likely happen??
Personalized medicine will involve pharmacogenomic treatment approaches that transcend the „one-size-fits-all”
approach
Personalized medicine will focus on keeping people well and treating disease at its earliest stages!
Laboratory medicine will lead the way!
„Disease signatures” comprised of hundreds or thousands of data point will be the biomarkers of the future
Drug companies will develope their markets around interventional treatments for „disease signatures”!!
The POTENTIAL for Personalized MedicineA „Wellness” Vision
• A new comprehensive and integrated approach to wellness – prevention of chronic disease, early detection of disease risk and individualized treatment plans
• Predictive toxicology for new drug candidates – ability to predict which individuals will benefit and those who might be most at risk for experiencing serious side-effects
Healthy Pre-disease Diseased RecoveringRoutine ComprehensiveHealth Status Monitoring
New diagnostics Disease prediction Preventative therapies
Earlier disease detection
New interventional therapies
New diagnostics
Accurate disease diagnosis
Personalized treatment
Informed treatment decisions
Real-time Disease Reoccurrence Monitoring
•People adopting healthier lifestyles
•Timely testing of environmental exposures
•Improved economics of disease screening
•Reduced occupational exposures
•Timely medical interventions
•Reduced hospitalizations
•More timely therapy
•Reduced unnecessary referrals
•More efficient treatment plans
•Improved outcomes
The POTENTIAL for Personalized Medicine
Increased Healthcare Quality and Reduced Costs (?)
Predict and prevent chronic diseasesKeep people out of the hospitalEliminate adverse drug eventsImprove drug developmentCreate new markets
The POTENTIAL for Personalized MedicineTransform Healthcare Markets
Today
HC markets on numbers of sick people might be treated with a new drug
MetricMorbidity and mortality
rates
OutcomePeople suffer and die from
chronic and preventable diseases with multiple hospitalizations
Tomorrow
HC markets based on numbers of people with preventable diseases
MetricNumber of people positive for valid
predictive biomarkers
Outcome• New era of interventional
therapeutics• People will live healthier, pain-
free lives and die of old age or trauma with minimal hospitalizations
Multiplex biomarkers to predict and guide treatment of early chronic Dz
We Can’t do This Now!!
Current Personalized MedicineApproaches Limited To:
PharmacogenomicsElectronic Health Records
Great Start – But does not yet address the all technologies
required for prediction and prevention
State of the Art in HC Measurement Technologies
Despite Major Progress over the Last 25 Years, Healthcare
Measurement Technological Capabilities is Limited to: Digitalizing medical records
Measuring a few serum biomarkers
Identifying simple genetic defects/differences
Imaging gross anatomical features and detect major changes
Imaging some disease-associated molecular mechanism
Comparing mRNA expression patterns between healthy and diseased cells
Statistical analysis of research for evidence-based medicine
The Personalized Medicine Gap
The lack of adequate measurement technology limits the vision for personalized medicine
We simply do not have the tools to measure the biochemical details of the human body with the
resolution needed to fully-realize the amazing potential of personalized medicine
Need to Know the Root Cause of Chronic Disease
But…
Human Cells are Extremly Complex
Diseases are the result of perturbations in complex biomolecular networks
PreventionBRCA1/2 - Breast and ovarian tu.
prophyilactic tamoxifen and surgery
EffectivityOncology
Herceptin – breast cancerCetuximab – colon tumor
Rare disease: cystic fibrosis Ivacaftor G551D mutation in CFTR geneSafety
VKOR/CYP2C9 – warfarin dosing
PM in the clinical practice
Multiplex Tests are Already Starting to Have an Impact
OncoType DXAnalyzes by qPCR, mRNA expression of a panel of 21 genes within a tumor to
determine a Recurrence Score
MammaPrintMicroarray-based prognostic breast cancer mRNA expression profiling test of 70 genes
AlloMapqPCR-based expression profile of 11 genes to assist physicians in managing heart transplant patients for potential organ rejection
Tissue of OriginMicroarray technology considers 15 common malignant tumor types, including bladder, breast,and colorectal tumors based on mRNA expression on 1,550 genes
A kihivások
New Technologies for Determination of „Disease Signatures”
Changes in biomolecular networks indicative of the onset or progression of disease
Normal Human System
100 trillion cells 6 billion basepairs
30,000 genes 10 million different proteins 100,000’s of molecular events 50 organs and organ systems
ABNORMALITIES
Multiplex Measurements
Computer Integration
Cell- or Tissue-specific Disease Probablity Score
•Increased Drug Pipeline
•Improved Diagnostics
•New Predictive Biomarkers
•Decrease Adverse Events
•Improve Clinical Outcome
•Fewer Errors & Misdiagnoses
•Predict Disease Onset
•Prevent Disease
•Reduce Health Care Costs
Discovery Decisions
Clinical Decisions
Changes due to P4 Medicine
• More innovative, patient-centered, proactive medicine that will be predictive, preventive, personalized and participatory rather than reactive
• The role of physician is changing
• Patients increasingly need „coaches” to help them dealing with complexity of „data clouds”, monitor their health and wellness
• Broadening the definition of patient (not only limited to thick persons)
• Social media and e-health will influence the healthcare
Fears from the P4
• Payer: increasing expenses?
• Physician: decreasing margin?
• Patient: certain drugs are inaccessible?
• Authorities: how to deal the complex situation?
• Diagnostic lab: more test with bed financing?
• Industry: – Narrowing market?– New financing strategy? ??
Too soon for conclusions
New ideas about self, privacy, medicine, and freedom
Ethics
Conclusion
We tend to overestimate the effect of technology in the short run and underestimate the effect in the long run
Amara’s Law
Figuring out how to use that information to improve your medical care is personalized medicine's next great challenge